论文部分内容阅读
３９例慢性肝炎患者，其中乙型肝炎１２例，丙型肝炎２７例，接受人α＿１型基因工程干扰素治疗（ｒＨＩＦＮα＿１）。１０例丙型肝炎病人ｒＨＩＦＮα＿１每日肌注１×１０￣６Ｕ，连用９０天，１７例丙型肝炎病人和乙型肝炎ｒＨＩＦＮα＿１每日肌注３×１０￣６Ｕ，连用９０天。治疗后乙型肝炎组ＨＢｅＡｇ和ＨＢＶＤＮＡ的阴转率均为４１．６７％；丙型肝炎用１×１０￣６Ｕ／ｄ和３×１０￣６Ｕ／ｄ组ＨＣＶＲＮＡ阴转率分别为５０％和６４．７％，两个剂量组阴转率比较差异无显著性（Ｐ＞０．０５），治疗期间不良反应发生率较低，远期疗效尚待观察。
39 cases of chronic hepatitis patients, including 12 cases of hepatitis B, hepatitis C in 27 cases, received human α_1 genetically engineered interferon therapy (rHIFNα_1). 10 cases of hepatitis C patients rHIFNα_1 daily intramuscular injection of 1 × 10 ~ 6U, once every 90 days, 17 cases of hepatitis C patients and hepatitis B rHIFNα_1 daily intramuscular injection of 3 × 10 ~ 6U, once every 90 days. After treatment, the negative conversion rates of HBeAg and HBVDNA in hepatitis B group were 41.67%; the HCV RNA negative rates in hepatitis C group were 50% and 64% for 1 × 10-6U / d and 3 × 10-6U / d, respectively .7%. There was no significant difference in the negative conversion rate between the two dosage groups (P> 0.05). The incidence of adverse reactions was low during the treatment period. The long-term therapeutic effect remains to be seen.